SCHEMBL4886161

SCHEMBL4886161

O=C(NN=C(C=NO)c1ccccc1)c1ccc(Cl)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.61
MAOA P21397 1/20 0.49
MAOB P27338 1/20 0.49
NPC1 O15118 5/20 0.47
RAB9A P51151 4/20 0.47
L3MBTL1 Q9Y468 3/20 0.47
AGTR1 P30556 2/20 0.47
OPRK1 P41145 2/20 0.47
KDM1A O60341 1/20 0.47
ALDH1A1 P00352 3/20 0.46
MAPT P10636 3/20 0.46
KDM4E B2RXH2 1/20 0.45
MEN1 O00255 1/20 0.45
GLA P06280 1/20 0.45
KMT2A Q03164 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
NFKB1 P19838 1/20 0.45
NFKB2 Q00653 1/20 0.45
RELA Q04206 1/20 0.45
CES2 O00748 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4890089 1.00 POLB (0.61) POLBMAOAMAOBNPC1RAB9A
SCHEMBL4886157 1.00 POLB (0.61) POLBMAOAMAOBNPC1RAB9A
SCHEMBL4890095 1.00 POLB (0.61) POLBMAOAMAOBNPC1RAB9A
SCHEMBL5715919 0.91 NPC1 (0.53) POLBNPC1RAB9AL3MBTL1AGTR1
SCHEMBL5715915 0.91 NPC1 (0.53) POLBNPC1RAB9AL3MBTL1AGTR1
SCHEMBL4883238 0.87 ALDH1A1 (0.54) POLBNPC1RAB9AL3MBTL1AGTR1
SCHEMBL4883234 0.87 ALDH1A1 (0.54) POLBNPC1RAB9AL3MBTL1AGTR1
SCHEMBL4890021 0.86 MAPT (0.57) POLBNPC1RAB9AAGTR1KDM1A
SCHEMBL4878943 0.86 MAPT (0.54) POLBNPC1RAB9AL3MBTL1KDM1A
SCHEMBL4890013 0.86 MAPT (0.57) POLBNPC1RAB9AAGTR1KDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080227787-A1 Use of New Lipoxygenase Inhibitors BIOLIPOX AB (SE) 2008-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227787-A1 Use of New Lipoxygenase Inhibitors ALOX15, ALOX15B, ALOX12 POLB 1905/4885MAOA 163/4885MAOB 125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.